Profile data is unavailable for this security.
About the company
Kancera AB is a Sweden-based company that develops and sells drug candidates in the field of cancer. The Company's activities are divided into two areas, namely Pharmaceutical Development and Industrial Research and Development (R&D). Pharmaceutical Development area runs such projects, as Project PFKFB3, which aims to develop a drug to combat solid tumors; and Project ROR-1, which aims to develop a drug to combat chronic lymphatic leukemia (CLL). Industrial R&D area consists of the identification of new projects of high potential and of R&D work commissioned by clients. The Company's other activities include development of cancer models and stem cell-based techniques. The Company is active through its subsidiary iNovacia, which carries out analytical development, as well as the identification, validation and further optimization of drug candidates. The Company's operations are conducted at the Karolinska Institutet Science Park in Solna, Sweden.
- Revenue in SEK (TTM)0.00
- Net income in SEK-53.07m
- Incorporated2010
- Employees5.00
- LocationKancera ABKarolinska Institutet Science ParkNanna Svartz Vag 4SOLNA 171 65SwedenSWE
- Phone+46 850126080
- Websitehttps://kancera.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spago Nanomedical AB (publ) | 2.03m | -37.51m | 66.16m | 12.00 | -- | 1.61 | -- | 32.67 | -0.2119 | -0.2119 | 0.0086 | 0.1181 | 0.0525 | -- | 20.15 | 155,769.20 | -97.31 | -20.19 | -113.72 | -20.97 | -132.69 | -- | -1,852.59 | -4,853.45 | -- | -- | 0.00 | -- | 14.14 | -- | -7.72 | -- | -- | -- |
| Dextech Medical AB | 0.00 | -4.93m | 71.73m | 1.00 | -- | 2.52 | -- | -- | -0.2665 | -0.2665 | 0.00 | 1.54 | 0.00 | -- | -- | 0.00 | -15.57 | -23.30 | -15.93 | -23.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.51 | -- | 18.92 | -- |
| Ultimovacs ASA | 0.00 | -149.13m | 78.02m | 17.00 | -- | 0.4089 | -- | -- | -4.34 | -4.34 | 0.00 | 5.55 | 0.00 | -- | -- | 0.00 | -49.47 | -28.80 | -54.77 | -31.12 | -- | -- | -- | -- | -- | -334.05 | 0.0132 | -- | -- | -- | -12.78 | -- | -45.35 | -- |
| AlzeCure Pharma AB | 0.00 | -35.66m | 88.74m | 11.00 | -- | 2.41 | -- | -- | -0.5055 | -0.5055 | 0.00 | 0.4172 | 0.00 | -- | -- | 0.00 | -85.98 | -52.78 | -103.30 | -57.01 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 33.91 | -- | -- | -- |
| Coegin Pharma AB | 0.00 | -26.00m | 99.47m | 1.00 | -- | 3.79 | -- | -- | -2.25 | -2.25 | 0.00 | 1.06 | 0.00 | -- | -- | -- | -111.12 | -122.02 | -119.99 | -154.70 | -- | -- | -- | -28,466.75 | -- | -55.53 | 0.00 | -- | -- | -- | 20.60 | -- | -- | -- |
| AroCell AB (publ) | 51.58m | -50.57m | 101.82m | -- | -- | 0.782 | -- | 1.97 | -0.2195 | -0.2195 | 0.2239 | 0.5653 | 0.3083 | 6.53 | 5.54 | -- | -30.22 | -29.25 | -32.55 | -31.37 | 12.55 | -9.85 | -98.04 | -231.19 | 4.52 | -- | 0.00 | -- | 16.37 | 122.92 | -0.5494 | -- | -- | -- |
| Prolight Diagnostics AB (publ) | 0.00 | -140.00m | 103.91m | 16.00 | -- | 0.6049 | -- | -- | -0.3853 | -0.3853 | 0.00 | 0.2447 | 0.00 | -- | -- | 0.00 | -66.82 | -- | -89.89 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -13.84 | -- |
| Sprint Bioscience AB | 60.25m | -19.11m | 106.27m | 36.00 | -- | 7.88 | -- | 1.76 | -0.2737 | -0.2737 | 0.863 | 0.1931 | 1.10 | -- | 7.28 | 2,151,857.00 | -34.81 | -71.22 | -82.55 | -113.71 | 58.54 | 62.75 | -31.72 | -110.22 | -- | -- | 0.00 | -- | 60,725.30 | 22.99 | 99.27 | -- | -26.02 | -- |
| Lumito AB (publ) | 17.00k | -31.86m | 124.32m | 13.00 | -- | 1.29 | -- | 7,313.17 | -0.1472 | -0.1472 | 0.00008 | 0.4133 | 0.0001 | -- | 2.43 | 1,133.33 | -26.73 | -20.77 | -30.85 | -22.38 | 42,235.47 | -- | -187,433.80 | -- | 1.10 | -14.60 | 0.1715 | -- | -- | -- | 4.56 | -- | -- | -- |
| NextCell Pharma AB | 10.66m | -41.96m | 128.64m | 24.00 | -- | 1.90 | -- | 12.06 | -0.8409 | -0.8409 | 0.2095 | 0.9249 | 0.1254 | 55.56 | 5.31 | 444,362.90 | -49.33 | -35.01 | -55.89 | -37.45 | -247.97 | -304.79 | -393.45 | -468.52 | 6.09 | -- | 0.00 | -- | 5.45 | 42.54 | -5.40 | -- | -27.06 | -- |
| Kancera AB | 0.00 | -53.07m | 130.64m | 5.00 | -- | 1.57 | -- | -- | -0.5955 | -0.5955 | 0.00 | 0.6849 | 0.00 | -- | -- | 0.00 | -56.73 | -54.82 | -66.40 | -66.21 | -- | 96.28 | -- | -7,249.06 | -- | -- | 0.00 | -- | -- | -- | -23.64 | -- | -- | -- |
| Biovica International AB | 7.25m | -115.45m | 151.33m | 27.00 | -- | 1.69 | -- | 20.87 | -1.73 | -1.73 | 0.1055 | 1.06 | 0.0584 | 17.30 | 4.76 | 226,593.80 | -92.98 | -51.94 | -110.37 | -58.18 | -394.72 | -576.01 | -1,592.15 | -2,217.41 | 3.47 | -- | 0.0721 | -- | 115.49 | 19.39 | -12.97 | -- | -54.31 | -- |
| Acousort AB | 3.44m | -19.30m | 170.25m | -- | -- | 11.13 | -- | 49.51 | -1.33 | -1.33 | 0.2379 | 1.02 | 0.1461 | 4.08 | 1.96 | -- | -81.99 | -48.62 | -137.70 | -69.77 | -159.41 | -68.05 | -561.21 | -299.58 | 1.91 | -- | 0.00 | -- | 11.51 | 38.81 | -24.01 | -- | -- | -- |
| Biosergen AB | 0.00 | -23.42m | 170.97m | 2.00 | -- | 7.49 | -- | -- | -0.2273 | -0.2273 | 0.00 | 0.0822 | 0.00 | -- | -- | 0.00 | -179.89 | -- | -244.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.25 | -- | -- | -- |
| Exact Therapeutics AS | 0.00 | -54.78m | 182.68m | 12.00 | -- | 10.49 | -- | -- | -1.66 | -1.66 | 0.00 | 0.5435 | 0.00 | -- | -- | -- | -130.29 | -40.21 | -170.98 | -45.67 | -- | -- | -- | -- | -- | -- | 0.0502 | -- | -- | -- | -20.52 | -- | -- | -- |
| Intervacc AB | 9.29m | -77.34m | 192.37m | 15.00 | -- | 1.07 | -- | 20.72 | -1.02 | -1.02 | 0.1226 | 2.38 | 0.0386 | 5.09 | 1.59 | 619,066.70 | -32.15 | -17.62 | -35.27 | -18.77 | -432.03 | -243.59 | -832.82 | -626.90 | 2.26 | -- | 0.0006 | -- | -17.23 | -25.79 | -60.31 | -- | -38.72 | -- |
Data as of Nov 22 2024. Currency figures normalised to Kancera AB's reporting currency: Swedish Krona SEK
0.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 31 Oct 2024 | 22.79k | 0.02% |
Data from 31 Oct 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
